Volanesorsen for treating familial chylomicronaemia syndrome will be scheduled back into the work programme. Timelines for the continuation of this evaluation are to be determined. A further update will be shared in due course.
The new timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.